Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBT Margin (2017 - 2025)

Historic EBT Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 464.69%.

  • Aclaris Therapeutics' EBT Margin fell 2695600.0% to 464.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 922.44%, marking a year-over-year decrease of 7811300.0%. This contributed to the annual value of 705.48% for FY2024, which is 4211500.0% down from last year.
  • Aclaris Therapeutics' EBT Margin amounted to 464.69% in Q3 2025, which was down 2695600.0% from 922.34% recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' EBT Margin peaked at 10.57% during Q4 2023, and registered a low of 1702.25% during Q2 2023.
  • Its 5-year average for EBT Margin is 871.15%, with a median of 987.17% in 2021.
  • The largest annual percentage gain for Aclaris Therapeutics' EBT Margin in the last 5 years was 13050700bps (2024), contrasted with its biggest fall of -10487200bps (2024).
  • Over the past 5 years, Aclaris Therapeutics' EBT Margin (Quarter) stood at 1525.18% in 2021, then surged by 75bps to 375.07% in 2022, then skyrocketed by 97bps to 10.57% in 2023, then plummeted by -9917bps to 1059.3% in 2024, then surged by 56bps to 464.69% in 2025.
  • Its last three reported values are 464.69% in Q3 2025, 922.34% for Q2 2025, and 1094.02% during Q1 2025.